Nebraska Oncology Society
A

2020 ASCO Updates on R/R Myeloma: Does FDA-Approved Selinexor Offer Survival Benefit? What Are the Response Rates With Teclistamab?

By Nebraska Oncology Society FEATURING Adam D. Cohen
By Nebraska Oncology Society FEATURING Adam D. Cohen
327 views
October 12, 2020
1 Comment
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Related Content

AUTOPLAY
18:26
William Schaffner

Shingles (Herpes Zoster) Vaccination in Adults: What is the Importan…

16:42
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…

Feat. H. Hashmi
19:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…

Feat. R. Banerjee
20:19
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus
12:38
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…

Feat. S. Usmani
14:09
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Multiple Myeloma Highlights and Clinical P…

Feat. H. Hashmi
49:01
Scripps MD Anderson Cancer Center

Current Summary of the Multiple Myeloma Treatment Landscape

Feat. R. Lu
12:35
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Treatment Options for Patients With Myelo…

Feat. C. Cerchione
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
26:46
Samer Al Hadidi

CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…

31:51
Indy Hematology Review

Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…

Feat. K. Anderson
15:01
Patrick Hagen

Treating High-Risk Pts With Early-Relapsed MM

03:17
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Highlights From the International Myeloma S…

Feat. J. Richter
20:26
MyCancerHaven

Experts Discuss the Management of Multiple Myeloma at First Relapse

Feat. R. Vij, B. Lipe
10:25
Srinivas Devarakonda

Choosing Appropriate Patients for Treatment With Monoclonal Antibody…

07:37
ASH 2022 Conference Coverage

IKEMA Subgroup Analysis: Isatuximab + Carfilzomib & Dexamethason…

Feat. T. Martin
13:18
Insights from 2023 IMS Annual Meeting

Highlights and Key Takeaways From the 2023 International Myeloma Soc…

Feat. A. Jakubowiak
21:51
Moffitt Cancer Center

State-of-the-Art: Bispecific Antibodies in Myeloma - Which? How? Whe…

Feat. A. Grajales-Cruz
09:00
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Time to Tailor? Treatment Selection at Firs…

Feat. M. Delforge
12:33
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Minimizing Uncertainty in Multiple Myelom…

Feat. K. Patel